Astrocytes are glial cells that help maintain brain homeostasis and become reactive in neurodegenerative processes releasing both harmful and beneficial factors. We have demonstrated that brain-derived neurotrophic factor (BDNF) expression is induced by melanocortins in astrocytes but BDNF actions in astrocytes are largely unknown. We hypothesize that BDNF may prevent astrocyte death resulting in neuroprotection. We found that BDNF increased astrocyte viability, preventing apoptosis induced by serum deprivation by decreasing active caspase 3 and p53 expression. The anti-apoptotic action of BDNF was abolished by ANA-12 (a specific TrkB antagonist) and by K252a (a general Trk antagonist). Astrocytes only express the BDNF receptor TrkB-truncated isoform 1, TrkB-T1. BDNF induced ERK, Akt, and Src (a non-receptor tyrosine kinase) activation in astrocytes. Blocking ERK and Akt pathways abolished BDNF protection in serum deprivation-induced cell death. Moreover, BDNF protected astrocytes from death by 3-nitropropionic acid (3-NP), an effect also blocked by ANA-12, K252a, and inhibitors of ERK, calcium, and Src. BDNF reduced reactive oxygen species levels induced in astrocytes by 3-NP and increased xCT expression and glutathione levels. Astrocyte-conditioned medium (ACM) from untreated astrocytes partially protected PC12 neurons, whereas ACM from BDNF-treated astrocytes completely protected PC12 neurons from 3-NP-induced apoptosis. Both ACM from control and BDNF-treated astrocytes markedly reduced reactive oxygen species levels induced by 3-NP in PC12 cells. Our results demonstrate that BDNF protects astrocytes from cell death through TrkB-T1 signaling, exerts an antioxidant action, and induces release of neuroprotective factors from astrocytes.
Astrocytes, the most abundant cell type in the brain, play a key role in maintaining central nervous system homeostasis (Sofroniew and Vinters 2010) . Astrocytes can release several molecules and participate in the inflammatory response to pathogens and injury, becoming reactive during disease (Ben Haim et al. 2015) . Loss of some functions, as well as their chronic activation, could contribute to the onset of neurodegeneration (Rossi 2015) . In fact, astrocyte reactivity is present in several neurodegenerative diseases such as Huntington and Alzheimer diseases (Verkhratsky and Parpura 2016) . However, astrocytes also release neurotrophic factors in response to cytokines and damage (Schwartz and Nishiyama 1994; Marz et al. 1999) , and astrocyte-conditioned medium (ACM) prevents neuronal death induced by several insults (Ruiz et al. 2012) . Consequently, survival of astrocytes and modulation of their functions may be an effective and unexplored strategy to decrease neurodegeneration.
Brain-derived neurotrophic factor (BDNF) is a neurotrophin (NT) that plays a major role in neuron differentiation and survival. BDNF exerts protective effects in several models of neurodegeneration (Nagahara and Tuszynski 2011) and has anti-apoptotic actions in neurons (Xia et al. 2010) . Mature BDNF binds tropomyosin receptor kinase B (TrkB) with high affinity and the p75 neurotrophin receptor (p75NTR) with low affinity. However, pro-BDNF only binds p75NTR. Both BDNF and TrkB are abundant in the brain and play key roles in neuronal development and survival (Binder and Scharfman 2004) . BDNF forms homodimer complexes that bind to the extracellular domain of TrkB, inducing receptor dimerization and subsequent tyrosine kinase activity of the intracellular portion of TrkB, leading to autophosphorylation of the cytoplasmic domain. Then, intracellular substrates such as PLCc, PI3K, MEK/ERK can promote signal transduction (Josephy-Hernandez et al. 2017) . In rodents, alternative splicing of TrkB mRNA generates three different receptors: C-terminal truncated isoforms of TrkB (TrkB-T1 and T2), which lack intracellular tyrosine kinase activity, and full length TrkB catalytic receptor (TrkB-FL) (Luberg et al. 2010) . TrkB-FL and TrkB-T2 are mainly expressed in neurons, whereas TrkB-T1 is highly expressed in astrocytes (Rudge et al. 1994; Armanini et al. 1995) . BDNF neuroprotective effects are exerted through TrkB-FL activation of classical ERK and Akt signaling (Xia et al. 2010) . Truncated TrkB-T1 lacks the kinase domain but contains a short isoform-specific cytoplasmic domain (Klein et al. 1990) . TrkB-T1 expression augments postnatally becoming the most abundant TrkB isoform in the adult rodent brain (Escandon et al. 1994) . However, physiological functions of TrkB-T1 remain unclear. TrkB-T1 was first reported to be a dominant negative inhibitor of TrkB-FL but recent work shows that TrkB-T1 has functional signaling on its own (Fenner 2012) and has an important role in neuropathic and inflammatory pain (Wu et al. 2013) .
Huntington disease (HD) is an autosomal inherited neurodegenerative disorder characterized by progressive motor, cognitive, and psychiatric disturbances (Ross et al. 2014) . HD is caused by expansion of polyglutamines on the Nterminal region of the huntingtin protein (Htt). Neuronal dysfunction and death in HD preferentially occur in mediumsized spiny neurons of the striatum but at later stages, other brain regions become affected. Mitochondrial dysfunction is observed in HD patients and systemic administration of 3-nitropropionic acid (3-NP), an irreversible inhibitor of succinate dehydrogenase of the mitochondrial complex II, induces striatal degeneration resembling HD neurodegeneration in animals. Thus, its administration is widely used as a model for HD (Brouillet et al. 2005) . 3-NP causes energy deficit in the cell by inactivation of the electron transport chain complex II, decreasing ATP synthesis and increasing free radical production such as reactive oxygen species (ROS), followed by apoptosis and/or necrosis (Pang and Geddes 1997) . Therefore, 3-NP can be toxic to astrocytes (Deshpande and Nishino 1998) and neurons (Wu et al. 2009 ), which makes the discovery of protective mechanisms against 3-NP-induced cell death relevant to the treatment of neurodegeneration. Interestingly, BDNF effects on 3-NP action in astrocytes are currently unknown. We previously demonstrated that BDNF expression is induced in astrocytes by melanocortins (Caruso et al. 2012) . Astrocytes express high levels of TrkB-T1, and low levels of TrkB-FL (Climent et al. 2000; Cheng et al. 2007 ) and p75NTR (Cragnolini et al. 2009 ). In addition, it was shown that TrkB-T1 activation, but not TrkB-FL, increases calcium signaling in astrocytes (Rose et al. 2003) . Recently, BDNF effects on GABA and glycine transport in astrocytes were reported to be mediated by TrkB-T1 through different mechanisms (Vaz et al. 2011; Aroeira et al. 2015) . Despite this evidence, BDNF effects and TrkB signaling in astrocytes are still poorly understood. BDNF could have protective effects in astrocytes in a model of neurodegeneration, as it does in other cell types, and in turn, astrocytes survival may exert neuroprotection. Therefore, in this work, we examined the effect of BDNF and TrkB on astrocyte viability and their impact on neuroprotection.
Methods

Materials
benzimidazol-2-one trifluoroacetate, Cat#A6730), Src family tyrosine kinase inhibitor (PP2 Cat#P0042), propidium iodide (PI, Cat#P4864), dichloro-dihydro-fluorescein diacetate (DCFH-DA Cat#D6883), 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT, Cat#M5655), and 3-nitropropionic acid (3-NP, Cat#N22908) were obtained from Sigma-Aldrich Corporation (Buenos Aires, Argentina). BDNF was purchased from Bachem, Torrance, CA, USA (Cat#H-5594). Unless stated otherwise, culture media and supplements, naphthalene-2,3-dicarboxaldehyde (NDA, Cat#N1138), all primers and PCR products used were from Invitrogen Life Technologies (Buenos Aires, Argentina). Annexin V-FITC CAT#556419 was from BD Biosciences (Buenos Aires, Argentina). PD98059 (Cat#51300) was purchased from CalbiochemMerck and K252a Cat#120419 from Abcam (Cambridge, UK).
Cell culture
Wistar rats (RRID:RGD_13508588) were housed in a temperaturecontrolled facility at 25°C on a 12 h light/12 h dark cycle with access to lab chow and water ad libitum and we provide enrichment of the environment. We bred these rats in our facility and parental rats were purchased from School of Pharmacy and Biochemistry of the University of Buenos Aires. Breeding cages are metallic with one male and two females per cage. All animal care and experimental procedures were approved by the Institutional Animal Care and Use Committee of the School of Medicine of the University of Buenos Aires (EXP-UBA0049923/2015). Astrocytes were prepared from cerebral tissue of 1-to 2-day-old Wistar rat pups from both sexes that were immediately decapitated. Cerebral hemispheres were dissected, freed from meninges, and cut into small fragments. After mechanical dissociation through a needle, cells were seeded and maintained for 3 weeks in Dulbecco's modified Eagle's medium (DMEM)/F-12 (Cat#12400-024) containing 10% fetal bovine serum (FBS, Cat#NTC-1000; Natocor, C ordoba, Argentina), 50 lg/mL streptomycin-50 U penicillin (Cat#15140-122) in 75 cm 2 poly-L-lysine-coated (10 lg/mL, Cat#P1524; Sigma-Aldrich) culture flasks at 37°C in 5% CO 2 . Culture medium was changed twice a week. After 11-14 days, astrocytes were separated from microglia and oligodendrocytes by shaking for 24 h in an orbital shaker at 200 rpm. Shaking was repeated twice after a gap of 1-3 days before subculturing to ensure the complete removal of oligodendrocytes and microglia. Cells were trypsinized and subcultured and, after 3 days of stabilization, incubated with the drugs in MEM (Cat#M3024; Sigma-Aldrich) containing 0% FBS, 6 mM L-glutamine (Cat#25030-081), 50 lg/ mL streptomycin-50 U penicillin. Five rat pups were used in each astrocyte culture and approximately 10 cultures were used in this study. No sample size calculation or randomization was performed.
Cultures were routinely 90-95% pure astrocytes, as assessed by glial fibrillary acidic protein immunostaining. Rat pheochromocytoma PC12 cells (RRID:CVCL_0481) were a gift from Dr. Fernanda Ledda (IBCN, School of Medicine, UBA). Cell line was not authenticated and the International Cell Line Authentication Committee does not list it as a misidentified cell line. PC12 cells were grown at 37°C in 5% CO 2 in DMEM (Cat#12100-046) supplemented with 10% FBS, 5% horse serum (Cat# Natocor) and 100 lg/ mL streptomycin, 100 U penicillin. Serum deprivation (SD) was achieved by incubating cells without serum after being cultured in 10% FBS. 3-NP was dissolved in phosphate-buffered saline (PBS) and pH was adjusted to 7.4 with NaOH.
Mitochondrial activity by MTT assay
The metabolic activity of viable cells was measured by MTT assay. Astrocytes (4 9 10 4 ) or PC12 cells (2 9 10 4 ) were washed and incubated for 4 h in 100 lL Krebs buffer plus 50 lg of MTT reagent dissolved in 10 lL PBS at 37°C. The developed crystals were dissolved in 100 lL 0.04N HCl in isopropanol, and optical density was read in a microplate spectrophotometer at 595 nm. When astrocytes were subjected to SD, mitochondrial activity was used to estimate cell viability.
Determination of DNA fragmentation by TUNEL assay
For 24 h, 5-10 9 10 3 cells were incubated and then fixed with 0.5 mL 4% paraformaldehyde-PBS for 30 min at 4°C. Tunel assay was performed as reported before (Caruso et al. 2007 Cell-cycle analysis by flow cytometry After fixation in ice-cold 70% methanol and centrifugation, astrocytes (2 9 10 5 cells) were resuspended in PBS containing RNase (10 lg/mL CAT#10109169001) and PI (50 lg/mL Cat#P4864) for DNA staining. Cells were incubated for 60 min at 37°C and analyzed by flow cytometry. Cells with a PI staining intensity lower than the G1 peak were considered hypodiploid (Sub-G1); 5000-10 000 cells were counted per sample. Each condition was tested in triplicates in every experiment. Determination of cells in Sub-G1 (hypodiploid cells), G1, S, and G2/M-phases of the cell cycle was performed using WinMDI 2.9 and Cylchred 1.2 softwares (WinMDI 2.9 (Joseph Trotter) and Cylchred 1.2 (Cardiff University).
Immunofluorescent identification of TrkB in astrocytes
Astrocytes were fixed with 0.5 mL 4% paraformaldehyde in PBS for 30 min at 4°C. After rinsing with PBS, cells were incubated with 10% normal goat serum in PBS with 0.1% Triton X-100 for 60 min. Then, slides were incubated overnight at 4°C with rabbit anti-TrkB antibody (1 : 1000, Cat#07-225, RRID:AB_310445; Millipore) in PBS with 0.1% Triton X-100 and 1% normal goat serum. After rinsing, slides were incubated for 1 h with goat anti-rabbit fluorescein-conjugated antibody (1 : 100, Cat#FI-1000; Vector Laboratories). Slides were mounted with mounting medium containing 4 0 ,6-diamido-2-phenylindole dihydrochloride and visualized in a fluorescence microscope Axiophot. Control slides were incubated with normal donkey and goat serum instead of primary antibody as negative controls. Acquisition was performed with a 409 objective.
Reverse transcriptase-real-time polymerase chain reaction (RT-qPCR) Total RNA was extracted from cultured astrocytes (1 9 10 6 cells), PC12 cells (2 9 10 6 cells) and a hypothalamic fragment (HMB) (Caruso et al. 2012) .
Western blot analysis
Astrocytes (8-10 9 10 5 cells) and a hypothalamic fragment (HMB)
were resuspended in lysis buffer (50 mM Tris-HCL pH 7.4, 1 mM EDTA, 150 mM NaCl, 1% NP-40, 0.1% sodium dodecyl sulfate and protein inhibitor cocktail Cat#P8340, 2 mM phenylmethylsulfonyl fluoride, 1 mM Na 3 VO 4 , 10 mM NaF) and proteins extracts collected after centrifugation at 16 500 g for 30 min. Protein concentration of samples was determined by the Bradford assay; 30-40 lg of protein was size-fractionated in a sodium dodecyl sulfate-polyacrylamide gel electrophoresis and then electrotransferred to a polyvinylidene difluoride membrane. Blots were blocked for 1 h in 5% non-fat dry milk-Tris-buffered saline ( , and anti-xCT/SLC7A11 (1:1000, Cat#ANT-111 Alomone Labs, Jerusalem, Israel) were incubated in 5% non-fat dry milk-TBS-0.1% Tween-20. After washing, blots were incubated with the respective biotinylated secondary antibody for 1 h. Immunoreactivity was detected by enhanced chemiluminescence (Biolumina, PBL, Buenos Aires, Argentina). After stripping, blots were incubated with total ERK (1 : 1000, Cat#135900, RRID:AB_2141283; Santa Cruz Biotechnology), total Akt (1 : 1000, Cat# 9272, RRID:AB_329827; Cell Signaling Technology), total Src (1 : 1000, Cat# 2109, RRID:AB_2106059; Cell Signaling Technology), or GAPDH (1 : 10 000, Cat# sc-25778, RRID: AB_10167668; Santa Cruz Biotechnology) antibodies, respectively, diluted in 5% non-fat dry milk-TBS-0.1% Tween-20 at 4°C. Blots were analyzed using SCION Image software. Data were normalized to total ERK, Akt, or GAPDH, and values expressed as increments relative to the respective controls.
Cell apoptosis determination by Annexin V and PI staining Astrocytes and PC12 cells (2 9 10 5 cells) were washed with PBS, trypsinized, and centrifuged. Astrocytes and PC12 cells were resuspended in Annexin V Binding buffer (0.01 M Hepes pH7.4, 0.14 M NaCl, and 2.5 mM CaCl 2 ) and stained with 5 lL of Annexin V-FITC. After 15 min, cells were stained with PI 50 lg/mL diluted in PBS and analyzed by flow cytometry. Annexin V positive and PI negative cells were scored as apoptotic. Controls included unstained cells, cells stained only with Annexin V, and cells stained only with PI; 5000-10 000 cells were counted per sample. Each condition was tested in triplicates in every experiment. Data were analyzed with WinMDI 2.9 software.
Cell viability determination by trypan blue exclusion assay Astrocytes and PC12 cells (2 9 10 5 cells) were washed with PBS and tripsinized. Astrocytes and PC12 cells were resuspended in DMEM + 10% FBS and 10 lL of cell suspension was stained with 10 lL of trypan blue. Viable cells that excluded trypan blue dye were counted in a Neubauer chamber, and cell viability was expressed as number of cells/mL. Each condition was tested in triplicates in every experiment.
Reactive oxygen species determination DCFH-DA is a non-fluorescent ester converted by ROS into dichloro-dihydro-fluorescein within the cell. Astrocytes (4 9 10 4 ) or PC12 cells (2 9 10 4 ) were incubated with DCFH-DA (10 lM) for 30 min. Then, the medium was removed and cells were incubated with 3-NP, BDNF with or without inhibitors for 24 h. Dichloro-dihydro-fluorescein fluorescence was read in a Synergy HT fluorometer (Biotek Vermont, USA) at 485 nm/528 nm. ROS levels are shown as arbitrary units of fluorescence/well. Each experiment included six replicates per condition.
Glutathion level determination
Glutathion (GSH) levels were determined by a fluorescence based assay (White et al. 2003) . Astrocytes were treated for 24 h and then conditioned medium was set aside and cells were collected in Locke Buffer (10 mM HEPES, 5.5 mM KCl, 10 mM glucose, 5 mM NaHCO3, and 130 mM NaCl). After sonication, cells were centrifuged at 16 500 g for 30 min. Supernatant aliquots were saved for protein determination by Bradford assay. ACM and supernatant samples were diluted with 1 volume of 200 mM sulfosalicylic acid and kept on ice for 15 min. After vigorously vortexing, samples were centrifuged at 16 500 g for 3 min. Twenty microliters of standards, supernatants, and ACM samples were loaded in a 96-well plate in duplicate; 180 lL/well of NDA solution (50 mM Tris pH 10, 0.5N NaOH, 10 mM NDA) were added to every well and the plate was incubated for 30 min in the dark. Fluorescence was measured in a Synergy HT fluorometer (Biotek) at 485 nm/528 nm. A calibration curve was performed with standard GSH solutions 0-50 lM. GSH levels are shown as lM/lg protein. Each experiment included 4-5 replicates per condition.
Statistical analysis
Data were expressed as mean AE SEM and analyzed by Student's ttest or one-way ANOVA, followed by Bonferroni or Dunnet Multiple Comparisons Test using GraphPad Prism 5 software. ANOVA assumptions, normal distribution, and equality of variances, were tested with KS and Barttlet tests, respectively. Differences with a p < 0.05 were considered statistically significant. All experiments were performed at least three times. There were no sample size differences between the beginning and end of experiments. No blinding procedures were used. This study was not pre-registered.
Results
BDNF protects astrocytes from apoptosis induced by SD
To investigate BDNF effect on astrocytes, cells were treated with different doses of BDNF and viability was determined after 24 h. SD (FBS 0%) reduced viability of astrocytes (Fig. 1a) . BDNF decreased SD detrimental effect on viability since BDNF at 20 and 50 ng/mL increased astrocyte viability (Fig. 1a) . To evaluate whether BDNF stimulatory effect on cell viability was because of increased proliferation, we analyzed the cell cycle in astrocytes. BDNF (50 ng/mL) treatment for 24 h did not modify the percentage of astrocytes in any phase of the cell cycle (data not shown). We next tested whether BDNF could reduce cell death. Analysis of hypodiploid astrocytes (Sub-G1) by flow cytometry showed that BDNF decreased the percentage of Sub-G1 astrocytes induced by SD (Fig. 1b) induced by SD ( Fig. 1c and d) . Next, we determined BDNF effect on two pro-apoptotic proteins: p53 and caspase 3. SD increased protein expression of p53 and of activated caspase 3 (cleaved form) in astrocytes, and BDNF treatment significantly reduced both p53 and active caspase 3 expression (Fig. 1e) . These results indicate that BDNF reduced SDinduced cell death in astrocytes by blocking apoptosis.
TrkB mediates BDNF protective effect on astrocytes Next, we determined TrkB participation in BDNF effects on astrocytes. We used ANA-12, a selective and potent TrkB antagonist which binds to the extracellular domain of TrkB thereby antagonizing all TrkB isoforms (Cazorla et al. 2011) , and K252a, a tyrosine kinase receptor inhibitor that inhibits all full length-Trks (Tapley et al. 1992) . We selected the highest dose of ANA-12 and K252a within the effective dose range that did not elicit astrocyte death (data not shown). ANA-12 (1 lM) abolished the protective effect of BDNF on astrocyte death induced by SD by increasing the percentage of Sub-G1 cells ( Fig. 2a and b ) and TUNEL-positive astrocytes (Fig. 2e) , indicating that TrkB mediates BDNF protective effects on astrocytes. K252a (100 nM) also blocked BDNF protection from SD-induced apoptosis ( Fig. 2c-e) , suggesting that TrkB-FL is involved in BDNF effects. Since TrkB-FL is mainly expressed in neurons rather than astrocytes, we determined BDNF receptor expression in our experimental conditions. We used PC12 cells as a negative control since they do not express TrkB (Kaplan et al. 1991) and rat hypothalamic tissue as a positive control. RT-qPCR analysis showed that astrocytes express both TrkB-FL and TrkB-T1 mRNA (Fig. 3a) . Only PC12 cells expressed significant levels of p75NTR mRNA (Fig. 3a) . TrkB-T2 mRNA expression was negligible in astrocytes and absent in hypothalamus and PC12 cells. Immunocytochemistry revealed a marked expression of astrocyte TrkB (Fig. 3b) . Western blot analysis showed that TrkB-T1 protein levels were very high in astrocytes and in hypothalamus, whereas TrkB-FL protein was detected only in hypothalamus and was absent in FBS 0%, BDNF-treated astrocytes, and PC12 cells (Fig. 3c) . Thus, TrkB-FL receptor is not expressed in cultured astrocytes.
BDNF induces activation of ERK, Akt, and Src in astrocytes BDNF protective effects were shown to involve ERK and Akt in neurons (Xia et al. 2010 ) and in astrocytes (Vaz et al. 2011) . Thus, involvement of these signaling pathways in astrocytes was investigated. BDNF stimulatory effect on cell viability was blocked by both ERK and Akt inhibitors (Fig. 4a) . ERK inhibitor completely abolished the decrease in the percentage of apoptotic astrocytes induced by BDNF, whereas in the presence of the Akt inhibitor BDNF protective effect is not observed (Fig. 4b) . Moreover, BDNF increased pERK ( Fig. 4c) and pAkt (Fig. 4d) ( Fig. 4e) . In astrocytes, BDNF was shown to increase calcium levels exclusively by activating TrkB-T1 (Rose et al. 2003) . Therefore, we evaluated ERK activation by BDNF in the presence of the calcium chelator BAPTA. ERK activation by BDNF was completely blocked by BAPTA (Fig. 4f) . Since we did not detect protein expression of TrkB-FL isoform and K252a was described to inhibit other protein kinases such as Ser/Thr kinases (Kase et al. 1987; MacKintosh and MacKintosh 1994) , we next tested whether K252a could inhibit ERK activation. We found that BDNF-induced ERK activation was also abolished in the presence of K252a (Fig. 4f) . Given that Src can activate ERK and Akt pathways, we tested BDNF effect on Src activation. BDNF-induced phosphorylation of Src in astrocytes and both K252a and BAPTA inhibited this effect (Fig. 4g) . Given that calcium is univocally involved in TrkB-T1 signaling in astrocytes and although K252a inhibited BDNF actions, it is very likely that TrkB-T1 is the main receptor mediating BDNF effect.
BDNF protects astrocytes from 3NP-induced cell death 3-NP administration induces striatal degeneration resembling the neurodegenerative disorder HD (Brouillet et al. 2005) . However, there are no data regarding BDNF action in 3-NPtreated astrocytes. Thus, we evaluated whether BDNF could also protect astrocytes from 3-NP-induced cell death. We first determined 3-NP effect on astrocyte mitochondrial activity by MTT assay and cell viability by trypan blue Values represent the pERK/total ERK ratio compared to control group. n = 5 independent experiments. In (d), pAkt/total Akt ratio values represent the ratio compared to control group. n = 3 independent experiments. One-way ANOVA: *p < 0.05 versus control. (e-g) Western blot of cell lysates from astrocytes treated for 15 min ANA-12 (1 lM), K252a (100 nM), or BAPTA (50 lM) and then for 30 min with BDNF AE ANA-12 (1 lM), K252a (100 nM), or BAPTA (50 lM). In (e and f) values represent the pERK/ total ERK ratio compared to control group. n = 4 independent experiments. In (g), values represent the pSrc/total Src ratio compared to control group. n = 3 independent experiments. One-way ANOVA: *p < 0.05 and **p < 0.01 versus control,^p < 0.05 and^^p < 0.01 versus BDNF. exclusion assay. As expected, 3-NP inhibited mitochondrial activity in a dose-dependent manner ( Figure S1a ). In addition, astrocyte viability was markedly reduced and apoptosis was increased by 3-NP ( Figure S1b and c) . Notably, BDNF prevented astrocyte death induced by 3-NP (Fig. 5a ), an effect blocked by ANA-12, K252a, ERK inhibitor, BAPTA, and the Src inhibitor, PP2 (Fig. 5b) . Thus, BDNF protects astrocytes from 3-NP-induced cell death by TrkB-mediated activation of Ca 2+ -Src-ERK pathways.
ACM from BDNF-treated astrocytes fully protects PC12 cells from 3-NP-induced cell death Since BDNF increases astrocyte viability this action may have an effect on neuron survival. Fetal astrocyte-conditioned medium was reported to protect neurons from cell death induced by 3-NP and BDNF applied directly to these neurons also prevents cell death (Ruiz et al. 2012) . Therefore, we decided to evaluate whether ACM from control or BDNF-treated postnatal astrocytes could induce neuroprotection. 3-NP significantly decreased mitochondrial activity of PC12 cells ( Figure S2a ) as well as cell viability ( Figure S2b ), while increasing apoptosis ( Figure S2c ). PC12 neurons do not express TrkB but they do express p75NTR (Yan et al. 2005) . Therefore, if BDNF remained in ACM after 24 h incubation, it could possibly exert a direct effect on PC12 cells acting through p75NTR. To exclude this possibility, we first tested the direct effect of BDNF on PC12 cell viability and found that BDNF had no effect either alone or in combination with 3-NP (Fig. 5c) . Next, we incubated astrocytes without (ACM-CTRL) or with BDNF (ACM-BDNF) for 24 h and used these ACM to incubate PC12 cells in the presence or absence of 3-NP for 24 h. Although ACM- CTRL partially protected PC12 cells from 3-NP-induced cell death, ACM-BDNF completely prevented PC12 cell death (Fig. 5d) . ACM-CTRL and ACM-BDNF alone did not modify PC12 cell viability (Fig. 5d) . These results suggest that astrocytes treated with BDNF secrete neuroprotective factors.
BDNF antioxidant action in astrocytes and PC12 cells against 3NP-induced oxidative stress 3-NP is known to induce mitochondrial dysfunction with consequent ROS production (Brouillet et al. 2005) . Since oxidative stress was suggested to account for 3-NP-induced cell death (Ju et al. 2004) , it was of interest to determine BDNF effect on ROS accumulation in astrocytes as a measure of oxidative stress. Treatment with 3-NP for 24 h increased ROS production in astrocytes in a dose-dependent manner ( Figure S1d) , and BDNF significantly reduced ROS levels induced by 3-NP (Fig. 6a) . We also tested whether BDNF antioxidant effect on astrocytes could be dependent on signaling pathways activated by TrkB. Neither ERK inhibitor, BAPTA, nor Src inhibitor had any effect on BDNF reduction in ROS levels induced by 3-NP (Fig. 6a) incubated with 3-NP (15 mM) and BDNF (50 ng/mL) for 24 h. xCT/ GAPDH ratio compared to control group. n = 5 independent experiments. One-way ANOVA: *p < 0.05 versus control. (d) Astrocytes were incubated for 24 h AE BDNF, and nuclear factor erythroid 2-related factor 2 (Nrf2) protein levels were determined in total protein extracts by western blot. Values are arbitrary units of the Nrf2/GAPDH ratio. n = 3 independent experiments. Student's t-test: ***p < 0.001 versus control. (e) PC12 cells were incubated for 24 h with astrocyteconditioned medium (ACM)-CTRL or ACM-BDNF AE 3-NP (10 mM) and then ROS levels were determined. Values are the mean fluorescence of n = 6 determinations/group of one representative experiment out of three independent ones. One-way ANOVA: *p < 0.05 and **p < 0.01 versus control and^^^p < 0.001 versus 3-nitropropionic acid (3-NP).
or in basal ROS levels (data not shown). GSH is the main antioxidant molecule secreted by astrocytes, and high levels of GSH can protect neurons from cell death (Dringen et al. 1999 ). Therefore, we tested whether BDNF could stimulate GSH content and/or release in astrocytes. BDNF treatment increased intracellular GSH levels, whereas it did not modify extracellular GSH released by astrocytes (Fig. 6b) . Although 3-NP did not modify intracellular GSH levels, it did markedly reduce extracellular GSH levels regardless of the presence of BDNF (Fig. 6b) . We determined the expression of the light chain xCT of the system Xc-, a transporter that imports cystine and exports glutamate, being the main source of cysteine, a rate-limiting substrate to synthesize GSH (Lewerenz et al. 2013) . Data show that 3-NP decreased xCT expression in astrocytes but in the presence of BDNF this effect is not observed (Fig. 6c) . Nrf2 regulates the antioxidant response by inducing expression of antioxidant enzymes, and is proved to be neuroprotective (Esteras et al. 2016) . Therefore, we evaluated whether BDNF could be modulating Nrf2 in astrocytes. We found that BDNF augmented expression of Nrf2 (Fig. 6d) , suggesting that Nrf2 may be involved in BDNF antioxidant action. We also evaluated ROS levels in PC12 cells. 3-NP increased ROS levels in PC12 neurons, which were similarly and markedly decreased by ACM-CTRL and ACM-BDNF (Fig. 6e) . Concordantly, GSH release was very similar in control and BDNF-treated astrocytes. Interestingly, ACM-CTRL per se decreased basal ROS levels in PC12 cells, whereas ACM-BDNF per se had no effect (Fig. 6e) . Since ACM and ACM-BDNF induced a similar reduction in ROS levels, this cannot explain the protection elicited by BDNF versus untreated astrocytes on 3-NP neurotoxicity.
Discussion
BDNF effects on neuronal survival, synaptic activity, learning, memory, and neurogenesis are well documented (Binder and Scharfman 2004) . However, little is known about BDNF role in astrocytes. Here, we demonstrated that BDNF prevented apoptotic cell death of rat astrocytes induced by two strong apoptotic stimuli such as SD and 3-NP. BDNF increased astrocyte viability after SD as a consequence of apoptosis reduction. Mechanisms of BDNF protection included reduction in p53 and active caspase 3 expression induced by SD. Tallying with this, it was recently shown that BDNF increases cell survival and reduces caspase 3 levels induced by amyloid-b in cultured neurons (Jeronimo-Santos et al. 2015) and by ischemic injury in rat cortex and hippocampus (Kim et al. 2014) . Although neurotrophin cocktail (BDNF, NT-3, and NT-4) reduced phosphorylation of p53 in cerebral cortical neurons (Wade et al. 1999) , ours is the first report showing BDNF reduction in p53 expression.
BDNF exerts its effects mainly through TrkB receptors. Of the TrkB isoforms, TrkB-FL and TrkB-T2 are those mainly expressed in neurons (Armanini et al. 1995) . Expression of TrkB-T1 in astrocytes is high (Cheng et al. 2007) and some reports have shown TrkB-FL expression (Climent et al. 2000; Cheng et al. 2007; Cragnolini et al. 2009; Gabryel and Bernacki 2009) . Our data show that TrkB-T1 is highly expressed in astrocytes and that although TrkB-FL mRNA is present, TrkB-FL protein is undetectable in these cells, in line with several other reports (Roback et al. 1995; Rose et al. 2003; Aroeira et al. 2015) . TrkB-FL can also be cleaved by calpain protease to elicit a truncated TrkB-FL isoform very similar to TrkB-T1 (Vidaurre et al. 2012) . Therefore, it is possible that TrkB-FL is expressed but may be cleaved to a truncated TrkB-FL isoform that may not be functional (Tejeda et al. 2016) . It remains to be determined whether this cleavage occurs in astrocytes. BDNF reduction in astrocyte apoptosis was blocked by the TrkB selective antagonist ANA-12 and by broad-spectrum Tyr kinase inhibitor K252a. In the adult rat central nervous system, p75NTR expression was described as being very low in astrocytes (Cragnolini and Friedman 2008) and in our experimental conditions, p75NTR mRNA expression was negligible. The fact that TrkB inhibition with ANA-12 blocked BDNF effects, plus the very low expression of p75NTR in our culture system indicates that p75NTR is not likely to be involved in BDNF action in astrocytes. TrkB-T1 mediates BDNF-induced internalization of glycine transporters in astrocytes (Aroeira et al. 2015) and modulates GABA transporters (Vaz et al. 2011) . A recent report describes that TrkB-T1 knockout mice-derived astrocytes exhibit decreased migration and proliferation in vitro (Matyas et al. 2017) . In line with these reports, our results suggest involvement of TrkB-T1 in BDNF protective effects, and show for the first time the protective role of astrocyte TrkB by mediating BDNF effects.
BDNF protective mechanism of action involves ERK, Akt, and, the non-receptor tyrosine kinase, Src activation in astrocytes. BDNF was reported to increase pERK and pAkt in primary cortical astrocytes (Cheng et al. 2007) , to modulate GABA transporters through ERK and Akt pathways (Vaz et al. 2011) , and to activate Src in cortical neurons through TrkB-FL (Zhang et al. 2013) . We show here for the first time that in astrocytes BDNF activates Src. We demonstrated that ERK activation is mediated by Src in astrocytes (Ramirez et al. 2015) . Therefore, ERK and Akt activation by BDNF may depend on Src in astrocyte, which is likely to contribute to cell survival (Lopez et al. 2012) . K252a is a non-specific tyrosine kinase inhibitor that inhibits Trks (Tapley et al. 1992) and BDNF-induced ERK activation (Lim et al. 2011) . Roback et al. (1995) reported that K252a inhibited BDNF-induced MAPK activation in glial cells. We show here that, K252a completely inhibited BDNF-induced ERK and Src activation in astrocytes as well as the protective effect of BDNF on SD-induced cell death. This effect is not because of inhibition of TrkB-FL since we demonstrated that astrocytes do not express TrkB-FL protein.
K252a was also described to inhibit MAPKs (Kase et al. 1987; MacKintosh and MacKintosh 1994) . Our results indicate that, in the absence or at low levels of TrkB-FL, K252a can affect other cellular targets such as MEK or Src kinases, resulting in inhibition of BDNF-induced ERK activity. TrkB-T1 was shown to increase calcium in astrocytes, whereas TrkB-FL did not (Rose et al. 2003) . Concordantly, BAPTA markedly inhibits both ERK and Src activation by BDNF, suggesting that TrkB-T1 can activate intracellular signaling pathways through calcium. Although K252a partially inhibited Src activation induced by BDNF, BAPTA had a more robust effect, thus establishing calcium as a central signaling molecule in TrkB signaling in astrocytes. Therefore, activation of calcium-Src-ERK-Akt signaling pathways by TrkB-T1 mediates protection of astrocytes by BDNF. These results corroborate with Vaz et al. (2011) who showed that BDNF enhances GABA transport in astrocytes through TrkB-T1 coupled to ERK/ MAPK pathway. In contrast, BDNF acting on TrkB-T1 inhibits glycine uptake in astrocytes not involving ERK or Akt pathways (Aroeira et al. 2015) . We cannot completely rule out TrkB-FL contribution to BDNF effects but even if it is expressed in astrocytes, its low levels of expression together with calcium involvement in TrkB signaling argue in favor of TrkB-T1 as a major mediator of BDNF action in astrocytes.
For many years, neurodegenerative diseases research has focused on neuronal death without taking the role of glial cells into account. In fact, dysregulation of astrocyte functions is a common component of many neurodegenerative diseases (Liu et al. 2017) supporting that astrocytes can be targets for treating neurodegeneration. HD is a neurodegenerative disorder caused by expansion of CAG repeats in Htt protein. Mitochondrial dysfunction is observed in HD patients and systemic administration of 3-NP induces HD-like symptoms in animals and humans (Brouillet et al. 2005) . Thus, 3-NP administration is a widely used model that resembles HD. HD patients and animal models showed astrogliosis (Glass et al. 2010) and reduced glutamate transporter GTL-1 expression (Ross et al. 2014) . Nevertheless, little is known about effects of HD on astrocyte physiology. We herein show that mitochondrial dysfunction induces astrocyte death and that BDNF is able to reduce it. Moreover, our data show that TrkB-T1-mediated activation of calcium-Src-ERK pathway mediates BDNF protection, further highlighting the importance of TrkB in astrocytes.
Glial CM is rich in antioxidants and neurotrophic factors. In vitro (Ruiz et al. 2012) and in vivo (Perucho et al. 2013 ) studies show that fetal glial CM protects a striatal cell model of HD from death induced by 3-NP. We show here that ACM from postnatal control astrocytes, though protective, cannot fully rescue neurons from 3-NPinduced cell death. This difference may be because ofdue to the fact that fetal astrocytes and postnatal astrocytes are different. Hence, different states of maturation of astrocytes may affect neuroprotection by ACM. Interestingly, we also show here that ACM from BDNF-treated astrocytes completely blocks cell death induced by 3-NP in PC12 cells. These results draw attention to the paramount action of BDNF in the brain. First, it promotes survival of astrocytes and neurons directly, and BDNF-treated astrocytes may prevent further neuron death by both fulfilling their functions and secreting protective agents to the extracellular media.
BDNF antioxidant activity may be a possible mechanism for neuronal protection, an action not yet extensively studied. 3-NP induces mitochondrial dysfunction with consequent ROS production (Brouillet et al. 2005) , and BDNF was shown to reduce ROS levels induced by 3-NP in cortical neurons (Wu et al. 2016) . We show here that BDNF decreased ROS production induced by 3-NP in astrocytes, correlating with reduced death of astrocytes and indicating that antioxidant activity could be a protective mechanism of BDNF. To the best of our knowledge, this is the first report showing BDNF antioxidant effect in astrocytes. Unexpectedly, our results show that, whereas ERK, calcium, and Src inhibition prevent BDNF antiapoptotic effect on astrocytes, inhibition of none of them could prevent BDNF-induced reduction in ROS levels. This suggests that other unidentified mechanisms may mediate BDNF antioxidant action. Moreover, we show here that BDNF increases expression of xCT subunit of system Xc-that imports cystine, essential to produce GSH. xCT light chain is the specific subunit, while 4F2 heavy chain is the promiscuous subunit of system Xc-. Decreased xCT expression was shown in the striatum of HD mice and in neurons expressing mHtt (Frederick et al. 2014) . BDNF increases xCT levels that were reduced by 3-NP treatment as a new mechanism of BDNF antioxidant action. Thus, we show here for the first time that BDNF per se increased GSH intracellular levels and xCT expression in astrocytes. Higher GSH levels most likely contribute to ROS neutralization by BDNF.
Nrf2 regulates the cell's antioxidant response inducing expression of antioxidant enzymes, and neuroprotection (Esteras et al. 2016) . Indeed, Nrf2 over-expression is sufficient to provide neuroprotection in an in vivo model of mitochondrial stress by 3-NP (Shih et al. 2005) . This study shows that 30 mM 3-NP enhances GSH levels and Nrf2-dependent gene expression in astrocytes (Shih et al. 2005) . However, we detected no GSH (Fig. 6b) or Nrf2 induction (data not shown) by 15 mM 3-NP. In our experimental conditions, higher doses of 3-NP were very toxic for astrocytes. Probably, lower doses of 3-NP may fail to induce Nrf2 and GSH, as 15 mM did in our system. BDNF was recently shown to induce Nrf2 activation in hippocampus of rats with depression-like phenotype (Bouvier et al. 2016) , and in chick cerebellar Bergmann glia (Poblete-Naredo et al. 2011). Our results indicate that BDNF increased Nrf2 expression in astrocytes and suggests that it may promote cell survival by increasing xCT and GSH levels. Nevertheless, GSH levels returned to basal levels in 3-NP + BDNF-treated astrocytes, probably because GSH levels induced by BDNF were consumed in order to reduce ROS levels induced by 3-NP. In neurons, BDNF pre-conditioning was shown to exert an antioxidant action not involving Nrf2 (Wu et al. 2016) . However, neurons have lower levels of Nrf2 than astrocytes, and depend on astrocyte-derived antioxidant factors to survive (Jimenez-Blasco et al. 2015) . Also, since the GSH system of peroxide detoxification in neurons is less efficient than that of astroglial cells (Dringen et al. 1999) , astrocytes fulfill a protective function for neurons through ROS elimination (Desagher et al. 1996) and GSH from astrocytes was shown to be essential for neuroprotection (Shih et al. 2003) . We show here that both ACM-CTRL and ACM-BDNF equally reduce ROS levels induced by 3-NP in PC12 neurons, concordant with the fact that both ACM have the same levels of GSH. Thus, ROS reduction is important for neuron and astrocyte survival but, in addition to ROS modulation, other protective factors released by astrocytes in response to BDNF remain to be identified.
Recently, transcriptome analysis of reactive astrocytes has revealed different types of astrocytes termed A1 and A2. A1 astrocytes are induced by neuroinflammation and up-regulate several genes known to be harmful (Liddelow and Barres 2017) . In contrast, A2 astrocytes are induced by ischemia and up-regulate many neurotrophic factors (Sofroniew 2015) and they prevent astrocyte scar formation (Anderson et al. 2016) . We propose that BDNF-treatment could favor astrocytes to shift toward an A2 phenotype and to release protective/s factor/s that prevent neuronal death. In summary, we show that BDNF exerted a novel protective effect in astrocytes through TrkB-T1, involving calcium-Src-ERK and Akt pathways, and a potent antioxidant action, probably through induction of Nrf2. Moreover, BDNF-treated astrocytes release protective factors that prevent death and oxidative stress in neurons. We hope that this work will encourage further studies on glial cells as therapeutic targets for neurodegenerative disorders.
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Additional supporting information may be found online in the Supporting Information section at the end of the article. Figure S1 . (a) Astrocytes were incubated with 3-NP and after 24 h mitochondrial activity was determined by MTT assay. Values are the mean OD of n = 8 determinations per group of one representative experiment out of three independent ones and were analyzed by one-way ANOVA. ***p < 0.001 versus control. (b) Cell viability of astrocytes treated for 24 h with different doses of 3-NP was evaluated by trypan blue exclusion assay. Values are the mean of number of viable cells/mL. n = 3 independent experiments and were analyzed by one-way ANOVA. ***p < 0.001 versus control. (c) Apoptosis of astrocytes treated for 24 h with 3-NP was evaluated by Annexin V/PI staining by flow cytometry. Values are the mean of percentage of Annexin V positive cells of n = 4 determinations per group of one representative experiment out of three independent ones and were analyzed by one-way ANOVA. ***p < 0.001 versus control. (d) Astrocytes were incubated for 24 h with different doses of 3-NP and then ROS levels were determined by measuring fluorescence intensity of DCF probe in each well. Values are the mean fluorescence of n = 8 determinations per group of one representative experiment out of three independent ones and were analyzed by one-way ANOVA. *p < 0.05 and ***p < 0.001 versus control. Figure S2 . (a) PC12 cells were incubated with 3-NP for 24 h and then mitochondrial activity was determined by MTT assay. Values are the mean OD of n=8 determinations per group of one representative experiment out of three independent ones and were analyzed by one-way ANOVA. ***p < 0.001 versus control. (b) PC12 neurons were incubated with 3-NP and after 24 h, cell viability was evaluated by trypan blue exclusion assay. Values are the mean of viable cells/mL. n = 3 independent experiments and were analyzed by one-way ANOVA. *p < 0.05 and ***p < 0.001 versus control. (c) Apoptosis of PC12 cells treated for 24 h with 3-NP was evaluated by Annexin V/PI staining. Values are the mean of percentage of Annexin V positive cells. n = 3 independent experiments and were analyzed by one-way ANOVA. ***p < 0.001 versus control.
